Clinical Trial

Adaptive Music Therapy for Psychosocial and Cognitive Functions of Older Adults

Study acronym: AMT
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The proposed study is a pilot study that aims to understand if the Pi Electronics adaptive music intervention (AM) is effective to promote positive psychosocial and cognitive outcomes, over and above a traditional music intervention (TM) among healthy older adults. This study will contribute to the ongoing literature on the benefits of music interventions and provide insight on how emerging technology can enhance the therapeutic effects of music as a viable intervention for older adults. The study will adopt a three-arm randomized controlled trial (RCT). Eligible participants will be randomized into one of three groups: traditional music therapy group (TM), Pi Electronic's adaptive music program (AM), and a waitlist control group (CG). Informed consent will be collected from all participants. All three groups will complete outcome measures at three sessions: pretest, posttest, and at a three-month follow-up, but only the TM and AM group will receive music between the pretest and posttest sessions, spanning for 4 weeks, with 4 music therapy sessions per week, and each session lasting 30 minutes. Data will be analyzed for each outcome variables to understand the group differences in the performance on the psychosocial and cognitive outcome measures. The study will also validate the Pi Electronics EEG headset with the BioSemi, 64-channel EEG system.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-07-01; most recent amendment 2025-12-17.
Status change: Recruiting → Active, Not Recruiting 2025-11-14
Status change: Not Yet Recruiting → Recruiting 2023-03-03
Trial Details
NCT Number NCT05447312
Lead Sponsor Toronto Metropolitan University
Collaborators: Mitacs
Conditions Stress, Psychological, Executive Functions, Loneliness, Emotion Regulation, Functional Abilities, Well Being
Enrollment 75 participants
Start Date 2022-12-01
Primary Completion 2025-11-07 (estimated)
Study Completion 2026-11-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-24